Citations

Clear

626 citation(s) found for "Mehta, SH".

Efficacy and Safety of Filgotinib as Induction Therapy for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the Phase 2b/3 SELECTION Study
Koch, Robert, Feagan, BC, Sandborn, WJ, Ritter, Timothy E., Mehta, Rajiv , Seidler, Ursula , Seibold, Frank , Kim, H, McNally, J. , Yun, Chohee , Zhao, Sally, Liu, X, Tasset, Chantal , Besuyen, R. , Watanabe, Mamoru , Hibi∥, Toshifumi , Loftus, Edward V. , Danese, Silvio , Vermeire, Séverine , Beales, Ian , Schreiber, Stefan , Rogler, Gerhard , Peyrin‐Biroulet, Laurent

Mayo Clinic

Zeitschrift für Gastroenterologie | November 22, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0041-1734235 Get It

NCOG-12. COGNITIVE FUNCTION (CF) & QUALITY OF LIFE (QOL) IN PATIENTS TREATED WITH PROCARBAZINE, CCNU, & VINCRISTINE (PCV) + RADIOTHERAPY (RT) VS. RT FOR ANAPLASTIC OLIGODENDROGLIOMA (AO) ON NRG RTOG TRIAL 9402
Won, Minhee , Cairncross, J. Gregory , Buckner, Jan C. , Fink, Karen, Bahary, Jean-Paul , Hartford, Alan C. , Souhami, Luís, Nguyen, Timothy K., Cescon, Terrence P., Pu, Anthony T. , Roa, Wilson , Polley, M.Y., Donovan, Laura, IWAMOTO, FABIO MASSAITI , Mishra, Mark V. , Barani, Igor J. , Huang, Jiayi , Mehta, Minesh P.

Mayo Clinic

Neuro-Oncology | November 18, 2021 | Volume: 23 | Issue: Supplement_6 | Pages: vi154-vi154

10.1093/neuonc/noab196.603 Get It

Abstract BACKGROUND PCV+RT substantially prolongs survival in AO patients, but long-term CF and QOL implications are unclear. We compared CF and QOL by treatment arm in RTOG 9402 participants and evaluated the impact that baseline characteristics had on CF, QOL, and survival. METHODS CF and QOL were evaluated using the Mini Mental State Exam (MMSE) and Brain-Quality of Life (B-QOL) scale at baseline and annually. Scores were analyzed between treatment arms at each time point for patients with ≥ 10 years of follow-up data. Shared parameter models evaluated MMSE and B-QOL scores and survival for all patients. RESULTS 42/148 (28.4%) participants in PCV+RT and 20/143 (14%) in RT alone arms survived ≥ 10 years. 35/42 and 39/42 (PCV+RT) and 18/20 and 17/20 (RT) participants completed baseline B-QOL and MMSE assessments, respectively. B-QOL scores did not differ between treatment groups at any time-point. Among 16 patients (10 PCV+RT, 6 RT) who completed year 10 MMSE evaluations, mean MMSE score at 10 years was higher in the RT arm (29.83 [95% CI 22.1, 30.0] vs. 26.50 [95% CI 29.4, 30.0], P= 0.04). Change in MMSE and B-QOL scores from baseline did not differ significantly between treatment groups at any time. In shared parameter models including all patients with baseline assessments, MMSE and B-QOL scores decreased over time (MMSE P= 0.0189, B-QOL P= 0.0005), but this did not differ by treatment group (MMSE P= 0.5727, B-QOL P= 0.3592). Younger age and higher KPS predicted better scores (MMSE P < 0.0001, P = 0.0002; B-QOL P = 0.0043, P = 0.0007). PCV+RT predicted better survival in both models. CONCLUSIONS PCV+RT improves survival in AO. Shared parameter models show decrease in MMSE and B-QOL over time. However, relative to RT alone, the addition of PCV did not impact change in CF and QOL over time.
Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases
Asrani, Sumeet K. , Ghabril, Marwan , Kuo, Alexander , Merriman, Raphael B., Morgan, Timothy R. , Parikh, Neehar D. , Ovchinsky, Nadia , Kanwal, Fasiha , Volk, Michael L. , Ho, Chanda , Mehta, Shivang , Cabrera, Roniel , Chernyak, Victoria , El‐Serag, Hashem B. , Ioannou, George N. , Marrero, Jorge A. , Mehta, Neil , Walling, Anne M. , Tapper, Elliot B. , Ghabril, Marwan S , Morgan, Timothy , Serper, Marina , Agopian, Vatche G , Ioannou, George N , Singal, Amit , Salem, Riad , Asrani, Sumeet K , Ovchinsky, Nadia , Parikh, Neehar D , Serper, Marina , Agopian, Vatche G. , Heimbach, Julie K. , Kaplan, David E. , Singal, Amit G. , Taddei, Tamar H

Mayo Clinic

Hepatology | November 15, 2021 | Volume: 75 | Issue: 5 | Pages: 1289-1299

10.1002/hep.32240 | PMID 34778999 Get It

Abstract The burden of HCC is substantial. To address gaps in HCC care, the American Association for the Study of Liver Diseases (AASLD) Practice Metrics Committee (PMC) aimed to develop a standard set of process‐based measures and patient‐reported outcomes (PROs) along the HCC care continuum. We identified candidate process and outcomes measures for HCC care based on structured literature review. A 13‐member panel with content expertise across the HCC care continuum evaluated candidate measures on importance and performance gap using a modified Delphi approach (two rounds of rating) to define the final set of measures. Candidate PROs based on a structured scoping review were ranked by 74 patients with HCC across 7 diverse institutions. Out of 135 measures, 29 measures made the final set. These covered surveillance (6 measures), diagnosis (6 measures), staging (2 measures), treatment (10 measures), and outcomes (5 measures). Examples included the use of ultrasound (± alpha‐fetoprotein [AFP]) every 6 months, need for surveillance in high‐risk populations, diagnostic testing for patients with a new AFP elevation, multidisciplinary liver tumor board (MLTB) review of Liver Imaging‐Reporting and Data System 4 lesions, standard evaluation at diagnosis, treatment recommendations based on Barcelona Clinic Liver Cancer staging, MLTB discussion of treatment options, appropriate referral for evaluation of liver transplantation candidacy, and role of palliative therapy. PROs include those related to pain, anxiety, fear of treatment, and uncertainty about the best individual treatment and the future. The AASLD PMC has developed a set of explicit quality measures in HCC care to help bridge the gap between guideline recommendations and measurable processes and outcomes. Measurement and subsequent implementation of these metrics could be a central step in the improvement of patient care and outcomes in this high‐risk population.
474 Phase 1 study of SEA-TGT, a human, nonfucosylated anti-TIGIT monoclonal antibody with enhanced immune-effector function, in patients with advanced malignancies (SGNTGT-001, trial in progress)
Garralda, Elena , Oberoi, H.K., Herrera, Alex F. , Forero‐Torres, Andres , Ansell, Stephen, Davar, Diwakar , Ribrag, Vincent , Sarkozy, Clémentine , Mehta, Amitkumar , Curigliano, Giuseppe , Belli, Carmen , Zain, Jasmine , Sanborn, Rachel E , Dumbrava, Ecaterina E.

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 9, 2021 | Volume: No volume available | Issue: No issue available | Pages: A503-A503

10.1136/jitc-2021-sitc2021.474 Get It

Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction
Givertz, Michael M. , Shah, Palak , McNulty, Steven E., Anstrom, Kevin J. , Mahr, Claudius , Gupta, Divya , Redfield, Margaret M. , Lala, Anuradha , Desvigne‐Nickens, Patrice , Braunwald, Eugene, Investigators, LIFE, Mohammed, Selma F. , Birru, Hellina, Aboye, Etsubdink, Lam, Phillip H. , Escobar, Nicole, Fink, Maria Cristina Domingues , Cappola, Thomas P. , Sheaffer, Wendy , Reilly, Bonitta, Ferree, J W, Ciezkowski, Gina, Herrera, Glenda, Mehta, Hirsch, Delucca, Rosemarie, Doddamani, Sanjay , Thomas, B. , Machen, Laurie, Kim, J., Christina, Athas, Lampert, Brent C. , Fontenelle, Cindy, Eiswirth, Clement, Rock, Darlene, Egnaczyk, Gregory F. , Rentas-Sherman, Enya, Barr, Deborah, Damato, Adrianna, Calayo, Christine, Herre, John M. , Carroll, Amanda , Keebler, Mary , Setliff, Bandaa, Gulati, Sanjeev , Winkler, K, Curtin, Laura, Ohmart, Carly, Halvorson, John, Mudd, James O., Camacho, S. Albert , Palardy, Maryse , Shah, Neha, Picardi, Kristina, Krishnamoorthy, Arun, Maximin, Adrienne, Horstmanshof, Douglas , Seiler, Beverly, Xu, Zi J., Mersola, S., Kransdorf, E. , Fonk, T., Oliveira, Guilherme H., Semenec, Terrence, Leo, Peter , Dunlap, Mark E. , Felker, G. Michael , Taylor, Lacey D., Sheehan, Mary, Levine, Sharon, Cocca-Spofford, Diane, Brooks, Liana, Cunningham, Thomas F., Acker, Nancy, Milbrandt, Susan, Gatzke, Janet, Dávila‐Román, Víctor G. , Bult, Karen, Weber, Elizabeth, Lesko, Mary, Mikhalkova, Deana , Fitzgerald, Kathleen, Whellan, David J. , Gutierrez, Jonathan, Goldsborough, Yavette, Caikauskaite, Indre, Skopicki, Hal A. , Huggins, Gordon S. , Yuen, Nathan, Haynes, Abbey, Katie, Carr, Snell, Gail, Smith, Andrew L. , Walker, Brandon S. , JOHNSON, J. Y. M., Henderson, Simmone, Pauwaa, Sunil, Bhat, Geetha , Gagliardi, A.R.T., Mann, Douglas L. , Vader, Justin M. , Starling, Randall C. , Margulies, Kenneth B. , Kiernan, Michael S. , Lewis, Gregory D. , DeVore, Adam D. , Hernandez, Adrian F. , Braunwald, Eugene , Investigators, LIFE, Aboye, Etsubdink A, Fink, Maria, Ferree, Jenny, Ravichandran, Ashwin Kumar , Herrera, Glenda, Kanwar, Manreet , Williams, Julie , Bhimaraj, Arvind , Lindenfeld, JoAnn , Gordon, Mary Ellen , Gulati, Sanjeev K., Winkler, Krystal, Tang, W.H. Wilson , Gorodeski, Eiran Z. , Norton, Nadine , Nichols, Julie, Taylor, Lacey, Cunningham, Thomas, Dirks, Anne, Wever‐Pinzon, Omar , Gilotra, Nisha A , Walker, Brandon, Henderson, Simmone, Gagliardi, Ann, Shah, Palak

Mayo Clinic

JAMA Cardiology | November 3, 2021 | Volume: 7 | Issue: 1 | Pages: 17

10.1001/jamacardio.2021.4567 | PMID 34730769 Get It

Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication‐overuse headache
Marmura, Michael J. , Diener, Hans‐Christoph, Cowan, Robert P. , Tepper, Stewart J. , Diamond, Merle L., Starling, Amaal J. , Hirman, Joe, Mehta, Lahar, Brevig, Thomas, Cady, Roger , Marmura, Michael J , Cowan, Robert P , Diener, Hans‐Christoph

Mayo Clinic

Headache: The Journal of Head and Face Pain | October 21, 2021 | Volume: 61 | Issue: 9 | Pages: 1421-1431

10.1111/head.14206 | PMID 34551130 Get It

Abstract Objective This post hoc analysis in patients medically diagnosed with chronic migraine (CM) and medication‐overuse headache (MOH) evaluated reductions in the use of acute headache medication (AHM) and sustained changes in the diagnostic status of CM and MOH following eptinezumab treatment in the PROMISE‐2 study. Background Eptinezumab, a monoclonal antibody that inhibits calcitonin gene‐related peptide, is approved in the United States for the preventive treatment of migraine. A previous analysis showed that eptinezumab reduced monthly migraine days and was well tolerated in the subgroup of PROMISE‐2 patients diagnosed with both CM and MOH. Methods The phase 3, double‐blind, placebo‐controlled PROMISE‐2 study (NCT02974153) randomized adults with CM to eptinezumab 100 mg, 300 mg, or placebo (administered intravenously every 12 weeks for up to two doses). MOH was prospectively diagnosed at screening by trained physicians based on 3 months of medication history and International Classification of Headache Disorders‐3β criteria. This post hoc analysis evaluated changes in total and class‐specific days of AHM usage, the percentage of patients using AHM at or above MOH diagnostic thresholds, and the percentage of patients experiencing monthly headache and migraine day frequency below diagnostic thresholds for MOH and/or CM. Results In PROMISE‐2, 431/1072 (40.2%) patients with CM were diagnosed with MOH (eptinezumab 100 mg, n = 139; 300 mg, n = 147; placebo, n = 145) and were included in this analysis. Total monthly AHM use decreased from 20.6 days/month at baseline to 10.6 days/month over 24 weeks of treatment (49% decrease) with eptinezumab 100 mg, from 20.7 to 10.5 days/month (49% decrease) with eptinezumab 300 mg, and from 19.8 to 14.0 days/month (29% decrease) with placebo. Numerically greater decreases from baseline with eptinezumab were also observed for individual drug classes. In each study month, the percentages of patients who were below MOH thresholds were numerically higher for both eptinezumab doses compared with placebo, as were the percentages of patients experiencing headache and migraine frequency below CM thresholds. Of patients with available data across the entire treatment period, 29.0% (58/200) of patients treated with eptinezumab stopped meeting and remained below diagnostic thresholds for both CM and MOH during Weeks 1–24, as well as 6.3% (6/96) of patients who received placebo. Conclusions Across 24 weeks of treatment, eptinezumab reduced AHM use in patients diagnosed with CM and MOH. More than one‐fourth (29%) of patients treated with eptinezumab did not meet the diagnostic thresholds for either CM or MOH for the entire treatment period.
Prevention of acute exacerbation of chronic obstructive pulmonary disease after bronchoscopic lung volume reduction with endobronchial valves
Lee‐Mateus, Alejandra Yu , Garcia‐Saucedo, Juan C. , Saifi, Omran , Patel, Neal M. , Herth, Felix , Woytanowski, J.R. , Alshelli, Ihab, Alevas, Sajive, Becerra, Juan Pablo Uribe, Majid, Adnan , Edell, Eric S. , Dulohery-Scrodin, Megan, Reisenauer, Janani , Jantz, Michael A., Abbas, Hawazin K., Fernández-Bussy, Sebastián , Yu Lee-Mateus, Alejandra, Dulohery-Scrodin, Megan M, Reisenauer, Janani S, Yu Lee-Mateus, Alejandra , Abia‐Trujillo, David , Mehta, Hiren J.

Mayo Clinic

The Clinical Respiratory Journal | October 5, 2021 | Volume: 16 | Issue: 1 | Pages: 43-48

10.1111/crj.13450 | PMID 34605606 Get It

AbstractIntroductionBronchoscopic lung volume reduction (BLVR) with endobronchial valves (EBVs) has emerged as an important treatment method for patients with severe chronic obstructive pulmonary disease (COPD). Acute exacerbations of COPD (AECOPD) are a frequent complication following BLVR with EBV. However, there is no consensus on the prevention of AECOPD.ObjectivesOur study aims to compare the outcomes of different prophylactic measures on the occurrence of AECOPD after BLVR with EBV.MethodsWe conducted a multicenter, retrospective study of patients who underwent BLVR with EBV at six different institutions. Emphasis was directed towards the specific practices aimed at preventing AECOPD: antibiotics, steroids, antibiotics plus steroids, or no prophylaxis. Subgroups were compared, and odds ratios (ORs) with corresponding 95% confidence intervals (CIs) were calculated.ResultsA total of 170 patients were reviewed. The rate of AECOPD was 21.2% for the full cohort. Patients who received prophylaxis had a significantly lower rate of AECOPD compared with those who did not (16.7% vs. 46.2%; p = 0.001). The rate was lowest in patients who received antibiotics alone (9.2%). There was no significant difference in the rate of AECOPD between patients who received steroids alone or antibiotics plus steroids, compared with the other subgroups. The OR for AECOPD was 4.3 (95% CI: 1.8–10.4; p = 0.001) for patients not receiving prophylaxis and 3.9 (95% CI: 1.5–10.1; p = 0.004) for prophylaxis other than antibiotics alone.ConclusionsAdministration of antibiotics after BLVR with EBV was associated with a lower rate of AECOPD. This was not observed with the use of steroids or in combination with antibiotics.
The Role of Specialty Palliative Care for Amyotrophic Lateral Sclerosis
Sethi, Anish , Everett, Elyse A. , Mehta, Ambereen K. , Besbris, Jessica, Burke, Christa, Pedowitz, Elizabeth , Kilpatrick, Molly, Foster, Laura A. , Maiser, Sam

Mayo Clinic

American Journal of Hospice and Palliative Medicine® | September 28, 2021 | Volume: 39 | Issue: 7 | Pages: 865-873

10.1177/10499091211049386 | PMID 34583569 Get It

Amyotrophic Lateral Sclerosis (ALS) is a progressive and incurable neurodegenerative disease resulting in the loss of motor neurons, eventually leading to death. ALS results in complex physical, emotional, and spiritual care needs. Specialty Palliative Care (SPC) is a medical specialty for patients with serious illness that provides an extra layer of support through complicated symptom management, goals of care conversations, and support to patients and families during hard times. Using MEDLINE, APA Psychinfo, and Dynamed databases, we reviewed the literature of SPC in ALS to inform and support an expert opinion perspective on this topic. This manuscript focuses on several key areas of SPC for ALS including insurance and care models, advance care planning, symptom management, quality of life, caregiver support, and end-of-life care. Recommendations to improve specialty palliative care for patients with ALS are reviewed in the discussion section.
Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement
Bagley, Stephen , Kothari, Shawn, Rahman, Rifaquat , Lee, Eudocia Q. , Dunn, Gavin P. , Galanis, Evanthia , Chang, Susan M. , Nabors, Burt , Ahluwalia, Manmeet S. , Stupp, Roger , Reardon, David A. , Khagi, Simon , Weller, Michael , Wen, Patrick Y. , Nabors, Louis Burt , Mehta, Minesh P , Sulman, Erik P , Weller, Michael , Khasraw, Mustafa , Galanis, Evanthia , Stupp, Roger , Ahluwalia, Manmeet S , Mehta, Minesh P. , Grossman, Stuart A. , Sulman, Erik P. , Sampson, John Howard , Cloughesy, Timothy F. , Wen, Patrick Yung , Khasraw, Mustafa

Mayo Clinic

Clinical Cancer Research | September 24, 2021 | Volume: 28 | Issue: 4 | Pages: 594-602

10.1158/1078-0432.ccr-21-2750 | PMID 34561269 Get It

Abstract Therapeutic advances for glioblastoma have been minimal over the past 2 decades. In light of the multitude of recent phase III trials that have failed to meet their primary endpoints following promising preclinical and early-phase programs, a Society for Neuro-Oncology Think Tank was held in November 2020 to prioritize areas for improvement in the conduct of glioblastoma clinical trials. Here, we review the literature, identify challenges related to clinical trial eligibility criteria and trial design in glioblastoma, and provide recommendations from the Think Tank. In addition, we provide a data-driven context with which to frame this discussion by analyzing key study design features of adult glioblastoma clinical trials listed on ClinicalTrials.gov as “recruiting” or “not yet recruiting” as of February 2021.
Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma
Singh, Kirit , Batich, Kristen A. , Wen, Patrick Y. , Bagley, Stephen , Lim, Michael , Platten, Michael , Colman, Howard , Ashley, David M. , Chang, Susan M. , Rahman, Rifaquat , Mansouri, Alireza , Reardon, David A. , Sahebjam, Solmaz , Simes, John, Berry, Donald A. , Zadeh, Gelareh , Cloughesy, Tim, Piantadosi, Steven , Weller, Michael , Heimberger, Amy B. , Tan, Aaron C. , Platten, Michael , Colman, Howard , Galanis, Evanthia , Berry, Donald , Mehta, Minesh P , Piantadosi, Steven , Weller, Michael , Khasraw, Mustafa , Mansouri, Alireza , Wen, Patrick Yung , Galanis, Evanthia , Puduvalli, Vinay K. , Sampson, John Howard , Mehta, Minesh P. , Heimberger, Amy B. , Khasraw, Mustafa , Simes, Robert John

Mayo Clinic

Clinical Cancer Research | September 24, 2021 | Volume: 28 | Issue: 4 | Pages: 585-593

10.1158/1078-0432.ccr-21-2681 | PMID 34561270 Get It

Abstract Immunotherapy has revolutionized treatment for many hard-to-treat cancers but has yet to produce significant improvement in outcomes for patients with glioblastoma. This reflects the multiple and unique mechanisms of immune evasion and escape in this highly heterogeneous tumor. Glioblastoma engenders profound local and systemic immunosuppression and is remarkably effective at inducing T-cell dysfunction, posing a challenge to any immunotherapy-based approach. To overcome these mechanisms, multiple disparate modes of immune-oriented therapy will be required. However, designing trials that can evaluate these combinatorial approaches requires careful consideration. In this review, we explore the immunotherapy resistance mechanisms that have been encountered to date and how combinatorial approaches may address these. We also describe the unique aspects of trial design in both preclinical and clinical settings and consider endpoints and markers of response best suited for an intervention involving multiple agents.